Spyre Therapeutics (SYRE) Change in Cash (2015 - 2026)

Spyre Therapeutics' Change in Cash history runs 12 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• Quarterly Change in Cash rose 128.01% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.7 million (up 127.14% YoY) and the FY2025 annual result came in at -$3.7 million, up 96.29% from the prior year.
• Change in Cash was $11.5 million for Q1 2026 at Spyre Therapeutics, down from $20.8 million in the prior quarter.
• Across five years, Change in Cash topped out at $200.1 million in Q2 2023 and bottomed at -$182.4 million in Q2 2024.
• A 5-year average of $4.7 million and a median of $11.5 million in 2026 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash sank 11737.94% — and 2024, when it jumped 28116.06%.
• Spyre Therapeutics' Change in Cash stood at -$4.1 million in 2022, then surged by 2472.4% to $97.3 million in 2023, then sank by 81.66% to $17.8 million in 2024, then grew by 16.71% to $20.8 million in 2025, then sank by 44.95% to $11.5 million in 2026.
• Business Quant data shows SYRE's Change in Cash at $11.5 million in Q1 2026, $20.8 million in Q4 2025, and -$16.8 million in Q3 2025.